New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
19:56 EDTHZNPHorizon presents data showing effectiveness of RAYOS
Horizon Pharma announced an additional analysis of data from the pivotal Circadian Administration of Prednisone in Rheumatoid Arthritis-2, CAPRA-2, clinical trial demonstrating that patients with active rheumatoid arthritis (RA) treated with its recently approved RAYOS 5 mg (prednisone) delayed-release tablets had a significant improvement in reduction of fatigue, as determined by the Functional Assessment of Chronic Illness Therapy - Fatigue, FACIT-F, questionnaire. Data were presented during the American College of Rheumatology, ACR/Association of Rheumatology Health Professionals,ARHP, Annual Scientific Meeting in Washington, D.
News For HZNP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
16:12 EDTHZNPHorizon Pharma reports positive effect of RAYOS in reducing joint stiffness
Subscribe for More Information
November 14, 2014
08:06 EDTHZNPHorizon Pharma 11.66M share Secondary priced at $12.05
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use